July 14, 2023

Dear Colleagues,

I hope you are all enjoying the summer. This is one of two DirectConnect issues we will have this summer. The next one will be in mid-August, and we will then return to our every other week format in the fall.

Summer always feels a bit quieter and there are much-needed vacations, but our work continues. Sadly, cancer is not influenced by the seasons. Cancer research must carry on and our patients need clinical care 52 weeks a year.

A few quick updates:

- We are hard at work preparing the Cancer Center Support Grant (CCSG) application. The CCSG funds much of our infrastructure in Yale Cancer Center and allows us to continue to call ourselves an "NCI-Designated Comprehensive Cancer Center." The application deadline is mid-September, and our incredibly talented team is pushing to the finish line.

- From a clinical standpoint, we are moving forward with our efforts to bring Smilow and YCC in full alignment. As you know, this effort is part of a larger initiative between the Yale New Haven Health System and the School of Medicine. The overarching goal is to build the strongest possible health care system. From a cancer care standpoint, our clear focus is to further develop a statewide network system that provides unsurpassed subspecialty and multidisciplinary cancer care. Our approach will include the systemwide availability of cutting-edge and practice-changing clinical trials – a key component of cancer care and research.

As the summer progresses, we are working ever more swiftly towards these goals. Foremost is the recognition that we must provide the very best care throughout our system, working diligently to minimize, and ultimately eliminate, cancer care disparities.

Final reminder: Consider signing up to ride or volunteer for Closer to Free on Saturday, September 9. The Ride is less than two months away.

Be well. Be safe. And have a great weekend.

Eric

Announcements

Susan Gueble, MD, PhD,
Appointed to Therapeutic
News Center

A Story About Love

Smilow Cancer Hospital Nurses are Riding in Closer to Free
Appointed to Therapeutic Radiology

The Department of Therapeutic Radiology is pleased to announce that Susan Gueble, MD, PhD, has been appointed as an Assistant Professor of Therapeutic Radiology and joined the Smilow Radiation Oncology team at Smilow Cancer Hospital in Trumbull. Dr. Gueble recently completed her residency training in radiation oncology here at Yale and served as a Chief Resident for the 2022-2023 academic year. She received her MD and PhD degrees as part of the medical scientist training program (MSTP) at Yale School of Medicine in 2018. Dr. Gueble’s clinical focus is in caring for patients with gynecologic, prostate, and genitourinary malignancies. She will also join the gynecologic brachytherapy program at the Smilow Cancer Hospital New Haven campus.

Dr. Gueble’s research focuses on DNA damage response pathways and the mechanisms of novel DNA modifying agents. As a physician-scientist, she will be developing a basic and translational research program with the goal of identifying new therapeutic strategies for the treatment of cancer. She is also part of the Neuroendocrine Tumor (NET) program. She was recently awarded a Spector Family Fund for Clinical Research and Investigation award in collaboration with the Yale Physician-Scientist Development Award (YPSDA) and Yale Center for Clinical Investigation (YCCI) Scholars Program, for her proposal entitled “Overcoming Temozolomide Resistance with a Novel MGMT-Dependent DNA Interstrand Crosslinking Agent in Non-Glioma Cancers.”

James Laird, MD, Joins Smilow Cancer Hospital in Waterford

James Laird, MD, will join the Smilow Radiation Oncology team at Smilow Cancer Hospital in Waterford this month. Dr. Laird trained at Yale Cancer Center/Smilow Cancer Hospital and served as a Chief Resident for the 2022-2023 academic year. Throughout his training he has shown a strong dedication to providing excellent patient care and has been a leader for the residency program.

Watch Now

Gene Editing Helped Crack a 100-year-old Mystery About Cancer

Read More

Eliminating Extra Chromosomes in Cancer Cells Prevents Tumor Growth

Read More

Supersize the Cell: Unlocking Secrets of the Genome Through Expansion Microscopy
Dr. Laird received his medical degree in 2018 from New York University School of Medicine, where he was inducted into Alpha Omega Alpha and named the highest performing student in preclinical training. During his training at Yale, he led the radiation oncology resident research consortium and presented his work at multiple national conferences. His academic interests include investigating the role of local treatments in oligometastatic cancer. His clinical practice will include thoracic, head and neck, and gastrointestinal malignancies.

Scott Huntington, MD, MPH, MSc, Appointed Interim Chief Quality Officer

We are pleased to announce Scott Huntington, MD, MPH, MSc, Associate Professor of Medicine (Hematology) and Medical Director of the Hematology Outpatient Program, as Interim Chief Quality Officer for Smilow Cancer Hospital.

An innovator in health services research and care delivery, Dr. Huntington specializes in the care of patients with lymphoma and chronic lymphocytic leukemia. He is an active member of Yale’s Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, where he leads research focused on improving the delivery of complex cancer treatment during routine care. Prior to joining Yale, he completed his hematology-oncology training and received a Master of Science in Health Policy Research at the University of Pennsylvania.

Notables

Michael Hurwitz, MD, PhD, Associate Professor of Medicine (Medical Oncology), has been appointed Assistant Director of Cancer Research Training and Education Coordination (CRTEC) for Yale Cancer Center. With the CRTEC efforts, Yale Cancer Center is a center of excellence in training the next generation of leaders in basic, translational, clinical, and population sciences.
training the next generation of leaders in basic, translational, clinical, and population science cancer research. CRTEC, chaired by Harriet Kluger, MD, and co-led by Dr. Hurwitz and David Stern, PhD, is focused on bolstering and coordinating the training activities across the spectrum of disciplines.

Kiran Turaga, MD, MPH, Chief of Surgical Oncology and Assistant Medical Director of the Clinical Trials Office, has been awarded a CA CURE Grant from the GI Research Foundation to support his research into the “Development of 5hmC Based Plasma Signatures (Liquid Biopsy) in the Detection of Patients with Peritoneal Metastases.”

Mandar Muzumdar, MD, Assistant Professor of Medicine (Medical Oncology) and Genetics and Scientific Director of the Center for Gastrointestinal Cancers, has received funding for a Research Project R01 Grant from the NIH to support his research on “Dietary fatty acids drive pancreatic cancer development.”

Andrew Goodman, PhD, C.N.H. Long Professor of Microbial Pathogenesis, Director of the Yale Microbial Sciences Institute, and a member of Yale Cancer Center’s Developmental Therapeutics Research Program, has been appointed Chair of the Department of Microbial Pathogenesis.

Shuangge (Steven) Ma, PhD, Professor of Biostatistics and Director of the Biostatistics and Bioinformatics Shared Resource for Yale Cancer Center, has been appointed Chair of the Department of Biostatistics at Yale School of Public Health.

Ronan Talty, MD-PhD Candidate in the laboratory of Marcus Bosenberg, MD, PhD, received the 2023 ASA La Roche-Posay Medical Student Grant Targeting Melanoma and Skin Cancer by The American Skin Association in recognition of his project, “Targeting Lipid Droplet Synthesis to Augment Melanoma Immunotherapy Responses.”

Anish Sharda, MD, MPH, Assistant Professor of Medicine (Hematology), is the 2023 recipient of the JH Milstone Grant. The JH Milstone Fund was established to support early-stage investigators with innovative research that improves the understanding of bleeding, thrombosis, or thrombolysis in memory of JH Milstone, MD, by his son, Leonard M. Milstone, MD ’70, Professor Emeritus of Dermatology, and daughter-in-law, Ellen B. Milstone, MD ’69.

Jeffrey Townsend, PhD, Elihu Professor of Biostatistics and Professor of Ecology and Evolutionary Biology; Co-Leader, Genomics, Genetics, & Epigenetics Research Program at Yale Cancer Center, received the 2023 Reducing Disease Risk Award from Yale School of Public Health in recognition of his publication, “Attribution of Cancer Origins to Endogenous, Exogenous, and Preventable Mutational Processes.”

Caroline Johnson, PhD, Associate Professor of Epidemiology (Environmental Health Sciences), was awarded the 2023 Women in Science (WomiX) Mentorship Award from the Metabolomics Association of North America at their annual conference in June.

Maryam Lustberg, MD, MPH, Associate Professor of Medicine (Medical Oncology) and Director of the Center for Breast Cancer, presented at the Multinational Association of Supportive Care In Cancer (MASCC) Annual.
Multinational Association of Supportive Care in Cancer (MASCC) Annual meeting in Japan in June on Cancer Care 2030 to launch a global initiative to address global goals for supportive care research in cancer. Dr. Lustberg also served as the 2022-23 president of the organization.

Laura Baum, MD, MPH, Assistant Professor of Medicine (Medical Oncology) and a member of Yale Cancer Center’s Cancer Prevention and Control Research Program, will present on "Trends in New and Persistent Opioid Use in Older Adults with and without Cancer" at the International Society for Pharmacoepidemiology annual meeting on August 26 during a spotlight presentation.

Veda Giri, MD, Division Chief, Clinical Cancer Genetics, Director, Cancer Genetics and Prevention Program, and Director, Early Onset Cancer Program, served as an invited Speaker at the 2023 Coffey-Holden Prostate Cancer Academy Meeting.

The Cancer Prevention and Control Research Program welcomes Vidya Puthenpura, MD, MHS, FAAP, Instructor of Pediatrics. Dr. Puthenpura is interested in investigating how health-related social risk can cause survival, recurrence, and adherence inequities in pediatric, adolescent, and young adult (AYA) patients with cancer. Her research has focused on outcome inequities amongst pediatric and AYA patients associated with differences in race, ethnicity, socioeconomic status, and geographic location. Her research is inspired by and interlinked with her clinical work as a pediatric hematologist/oncologist.

Employee Profile: Rosangely Cruz

Rosangely “Rosy” Cruz has worked at Yale for more than 23 years and says the experience has shaped her as a person. Upon earning her associate degree from Gateway Community College, she entered a two-week externship in Derm-Path through the Yale Partnership program. At its completion, she received a full-time job.

Molly West: I am a survivor of stage IV Colon Cancer. I had my first occurrence in Sept ’21 and a recent reoccurrence in Feb ’23. I have gone through the same basic treatment (chemo and surgery) both times. Having to go through this a second time has given me more clarity about my journey and how to handle it. The first time was so terrifying and such a whirlwind that I didn’t know what to do or how to handle the situation… Whereas the second time, I have knowledge about what to expect, and I can choose a different way of managing the process that works better for me. It’s been important to continue to stay connected to family, friends, and co-workers and share my learnings along the way...

Recently on Yale Cancer Answers, cancer epidemiologist Dr. Maureen Canavan discussed ways to evaluate quality metrics for cancer care, especially when providing end-of-life care. Listen on Connecticut Public Radio or download our podcast from iTunes.
Of her service spanning two decades, Rosy says, “I love this organization; the journey has been long and hard, but it has been so rewarding.”

Currently, Rosy is a Practice Administrator for Smilow Cancer Hospital. She supports clinical operations, including clinical operations managers, and nearly 90 medical assistants, clinical secretaries, and other supportive, patient-facing roles. She loves the scope and variety of her work, and always starts her team’s daily huddle with a quote of the day or a team-building activity to set a positive tone.

“I look at life with a glass half-full approach,” she says. “I look to set the tone for the day and hope the managers I work with carry this same positivity through to their teams. This work is incredibly important for me and recognizing the impact we have on patients. It’s important to remember these are humans that we care for, and we are extremely fortunate to be a part of their care. It is a big responsibility.”

Rosy is grateful to have worked with two leaders she considers mentors: Diana Glassman, RN, MBA, CNEL, Director of Urology, and Margaret Gilshannon, MHA, Deputy Director for Finance and Administration at Yale Cancer Center. When Rosy was first hired at Yale and joined medical records within Surgical Dermatology, Diana was her first supervisor and through the years has made a lifelong impression. “Rosy is a one-of-a-kind individual who has the ability to bring people together and solve problems,” said Diana. “She is a master at work flows and always has the patient front and center in all her decision making. Any department is blessed to have her as part of their team.”

For the last two years, Rosy has reported to Margaret and gained tremendous respect for her leadership. Rosy appreciates being given the room to lead her team with her own style. “Rosy joined the Cancer Center team during a period of transition and has been a remarkable manager and leader. She is smart, thoughtful, and courageous with an unwavering commitment to our patients. Smilow and the Cancer Center are incredibly lucky to have Rosy on our team!” Margaret said.

Among her notable achievements, Rosy earned her bachelor’s degree in social science from Albertus Magnus College and is currently working on her master’s degree in organizational leadership at Quinnipiac. She is also a six-year participant in Closer to Free, her most favorite event of the year. She rides with Team Gorilla Glue, sister team of Urology’s Team Stream, led by her brother-in-law and husband.

Recent Publications

The Room Where It Happens: Addressing Diversity, Equity, and Inclusion in NCTN Clinical Trial Leadership.  
Read More
Inclusion in NCTN Clinical Trial Leadership.
Journal of the National Cancer Institute, djad121.
Read More

Read More

Ehrahimi, B., Howard, A., Carlson, D.J., Al-Hallaq, H.
ChatGPT: Can a Natural Language Processing Tool Be Trusted for Radiation Oncology Use?
Int J Radiation Oncol Biol Phys, Vol. 116, No. 5
Read More

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
Annals of surgical oncology, 10.1245/s10434-023-13757-0.
Read More

Radiotherapy and radio-sensitization in H3K27M -mutated diffuse midline gliomas.
CNS neuroscience & therapeutics, 29(7), 1721–1737.
Read More

Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)
Blood reviews, 60, 101072.
Read More

Rosa, W. E., & Grant, L.
Palliative Justice Post-COP27.
The Yale journal of biology and medicine, 96(2), 257–260.
Read More

Pusztai L.
Systemic Staging of Locally Advanced Breast Cancer: How Hard to Look?
Read More

Mirza, F. N., Mirza, H. N., Yumeen, S., Zogg, C. K., & Leffell, D. J.
The Yale journal of biology and medicine, 96(2), 251–255.
Read More

Role of homeobox d10 gene targeted signaling pathways in cancers.
Pathology, research and practice, 248, 154643.
Read More

Welcome Amro Tambal, MS, who is participating in the 2023 Yale Cancer Center Diversity Enhancement Program in Oncology. Amro is a Sudanese-American with a bachelor's degree in biomedical engineering and a master's degree in biomedical sciences from Rutgers University. In his current role as a second-year medical student at Rutgers New Jersey Medical School, he continues to pursue his passion for healthcare and oncology. Amro actively contributes to a student-run healthcare clinic in Newark, providing essential medical services to high-risk populations.

Furthermore, his commitment to addressing healthcare disparities is recognized through his status as a Removing Barriers to Success scholarship recipient at New Jersey Medical School.
Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS.

Blood reviews, 60, 101056.

Aneja, S., Avesta, A., Xu, H., & Machado, L. O.
Clinical Informatics Approaches to Facilitate Cancer Data Sharing.

Kim, L., Coman, M., Pusztai, L., & Park, T. S.
Neoadjuvant Immunotherapy in Early, Triple-Negative Breast Cancers: Catching Up with the Rest.
Annals of surgical oncology, 10.1245/s10434-023-13714-x.

Barriers to hormone therapy following prophylactic bilateral salpingo-oophorectomy in BRCA1/2 mutation carriers.
Menopause (New York, N.Y.), 30(7), 732–737.

Wiemels, J. L., Wang, R., Feng, Q., Yee, A. C., Morimoto, L. M., Metayer, C., & Ma, X.
Birth characteristics and risk of Ewing sarcoma.

Cell cycle controls long-range calcium signaling in the regenerating epidermis.
The Journal of cell biology, 222(7), e202302095

Labaki, C., Saliby, R. M., Bakouny, Z., Saad, E., Semaan, K., Eid, M., Lalani, A. K., Choueiri, T. K., & Braun, D. A.
Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma.
Hematology/oncology clinics of North America, S0889-8588(23)00076-X.

Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer.
NPJ breast cancer, 9(1), 56.

Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohorts.
Cancer, 129(12), 1836–1845.

Bourdillon, A. T., Shah, H. P., Cohen, O., Hajek, M. A., & Mehra, S.
Novel Machine Learning Model to Predict Interval of Oral Cancer Recurrence for Surveillance Stratification.
The Laryngoscope, 133(7), 1652–1659.

We invite you to please Save the Date for “Caring for Metastatic Breast Cancer: A Conference for Patients & Caregivers,” a special in-person program on Saturday, October 7, from 9:00am to 3:00pm at Yale University’s Greenberg Center.

Hosted by Maryam Lustberg, MD, MPH, Director, Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center, and Sandy Cassanelli, Founder, Breast Friends Fund, remarks will include Eric Winer, MD, Director, Yale Cancer Center; Physician-in-Chief, Smilow Cancer Hospital.

Mary Zaccarelli truly exemplifies the role of a Patient Experience Ambassador and is a #SmilowStar!

Mary is often the very first person patients, families, and staff members see when they enter Smilow Cancer Hospital. She is warm, engaging, and very helpful. In her role greeting patients entering Smilow on NP4 from Air Rights Garage, Mary sets the tone for patient experience for patients and caregivers alike.
**Novel Targeted Therapies for Renal Cell Carcinoma: Building on the Successes of Vascular Endothelial Growth Factor and mTOR Inhibition.** *Hematology/oncology clinics of North America*, S0889-8588(23)00077-1.  
Read More

Zhan, P. L., Canavan, M. E., Ermer, T., Pichert, M. D., Li, A. X., Maduka, R. C., Udelsman, B. V., Nemeth, A., & Boffa, D. J.  
**Association Between Metastatic Pattern and Prognosis in Stage IV Gastric Cancer: Potential for Stage Classification Reform.** *Annals of surgical oncology*, 30(7), 4180–4191.  
Read More

**Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials.** *Clinical cancer research: an official journal of the American Association for Cancer Research*, 29(13), 2426–2434.  
Read More

Kim, L., Coman, M., Pusztai, L., & Park, T. S.  
Read More

Kahn, A. M., Golestani, R., Harigopal, M., & Pusztai, L.  
Read More

Read More

**Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.** *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*, JCO2202721.  
Read More

**PACS-integrated machine learning breast density classifier: clinical validation.** *Clinical imaging*, 101, 200–205.  
Read More

Dr. Eric Winer, Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital, discusses his theme ‘Partnering with Patients’ at the American Society of Clinical Oncology annual meeting. "I hope that the message that these partnerships are really important is something that resonates with people ...there's always room for some amount of improvement."

Jim Fraser, patient of Dr. Anne Chiang:  
**If I could tell my cancer team one thing, it would be when I was diagnosed, I thought I was alone. The team quickly made me feel as though we were all in this together. From the surgical team to the radiation team to the infusion team, I was made to feel that everyone was invested. I cannot express enough my appreciation to all the doctors and thank God for the nurses whose caring really got me through it all.**
Funding and Award Opportunities

**Addressing the Primary Care Needs of Cancer Survivors (U01)**
The purpose of this FOA is to support the development and testing of primary care practice (PCP)- and health system-level interventions and strategies to promote high quality care for adult cancer survivors during and/or after cancer treatment. The overall goal of this opportunity is to support high quality care for cancer survivors that integrates primary care from the point of diagnosis forward.

**Application Deadline:** July 24, 2023

**Read More**

**Understanding Persistent Oral Human Papillomavirus and Human Immunodeficiency Virus Co-infection and Its Role with Oropharyngeal Cancer Induction (R01)**
The purpose of this NOFO is to solicit research to better understand the mechanisms of persistent oral human papillomavirus (HPV) and human immunodeficiency virus (HIV) co-infection as well as its role in the induction and pathogenesis of HPV-associated oropharyngeal cancers (HPV-OPC).

**Application Deadline:** July 24, 2023

**Read More**

**DoD Prostate Cancer Research Program Funding Opportunities for FY23**
- **Early Investigator Research Award (EIRA)** - supports research opportunities focused on prostate cancer for individuals in the early stages of their careers. **LOI Due:** August 3, 2023
- **Exploration – Hypothesis Development Award (EHDA)** - supports the exploration of highly innovative, untested, potentially groundbreaking concepts in prostate cancer. **LOI Due:** June 22, 2023
- **Idea Development Award (IDA)** - supports new ideas that represent innovative, high-risk/high-gain approaches to prostate cancer research and have the potential to make an important contribution to one or more of the FY23 PCRP Overarching Challenges. **LOI Due:** June 29, 2023
- **Physician Research Award (PRA)** - supports a mentored research experience to prepare physicians with clinical duties for careers in prostate cancer research. **LOI Due:** August 3, 2023

**Read More**

**Understanding Persistent Oral Human Papillomavirus and Human Immunodeficiency Virus Co-infection and Its Role with Oropharyngeal Cancer Induction (R01)**
The purpose of this NOFO is to solicit research to better understand the mechanisms of persistent oral human papillomavirus (HPV) and human immunodeficiency virus (HIV) co-infection as well as its role in the induction and pathogenesis of HPV-associated oropharyngeal cancers (HPV-OPC).

**Application Deadline:** July 24, 2023

**Read More**

**Peer Reviewed Cancer Research Program Overarching Challenges**
The PRCRP has developed a strategy to address multiple issues in cancer research over the spectrum of different cancer topics considered for funding. These Overarching Challenges are critical gaps in cancer research, care, and/or patient outcomes that will advance mission readiness of U.S. military members affected by cancer and improve quality of life by decreasing the burden of cancer on Service Members, their families, Veterans, and the American public.

**Letter of Intent Due:** July 25, 2023

**Read More**

**R50 NCI Specialist - Clinician Scientist - Clinical Trial Not Allowed (PAR-21-306)**
Through this FOA, the NCI invites applications for the Research Specialist Award (R50) specifically for clinician scientists supporting NCI-funded clinical trials research. The Research Specialist Award is designed to encourage the transition of clinician scientists to research positions that focus on clinical trials.

**Read More**

---

**Stephan Brigidi:**
If I could tell my cancer care team one thing it would be…that I am grateful for the great attention and care that I received with the TULSA Procedure*. The process was very thorough and I was completely aware and prepared for the procedure and all that it entailed. I felt genuine concern for my care and was so happy with the team of Dr. Preston Sprenkle, Dr. Jessica Lee, and Dr. Sandeep Arora. I also appreciated the kind care shown to me by the anesthesiologists, and the vast team of nurses and technicians who assisted me throughout.

---

**Stephan Brigidi:**
I do not know how they can be so positive while fighting this terrible disease. I remember my first meeting at Smilow Cancer Hospital. There were so many people fighting to survive, I realized I was not alone—and I watched as every patient was treated the same.
The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional clinician scientists who want to continue to participate in the NCI clinical trials networks through leadership in the 1) development of national clinical trials, 2) implementation of NCI clinical trials in their institutions, and 3) national service to the NCI clinical trials networks through participation in the scientific review committees, monitoring committees and other activities, but not serve as principal investigators of research project grants.

**Internal Submission Deadline:** August 3, 2023

Read More

**Neurofibromatosis Research Program**
The NFRP seeks to support innovative, high-impact research that will foster new directions for and address neglected issues in NF research; sponsor multidisciplinary and multi-institutional collaborations that will bring new perspectives to the field; promote translational and clinical studies to move promising ideas from bench to bedside; and develop a balanced portfolio of meritorious research related to all aspects of NF1, NF2, and Schwannomatosis.

- Neurofibromatosis Research Academy-Leadership Award - **Letter of Intent Due:** August 11, 2023
- Neurofibromatosis Research Academy-Scholar Award - **Letter of Intent Due:** August 11, 2023
- Clinical Trial Award - **Letter of Intent Due:** August 11, 2023
- Early Investigator Research Award - **Letter of Intent Due:** August 11, 2023
- Exploration – Hypothesis Development Award - **Letter of Intent Due:** August 11, 2023
- Investigator – Initiated Research Award - **Letter of Intent Due:** August 11, 2023
- New Investigator Award - **Letter of Intent Due:** August 11, 2023
- Synergistic Idea Award - **Letter of Intent Due:** August 11, 2023

Read More

**2023 Yale SPORE in Skin Cancer Career Enhancement Program Awards**
CEP projects must have promising translational research potential with application to human skin cancer. It is expected that they can evolve into projects with a clear translational component that are suitable for funding either within the Yale SPORE in Skin Cancer or as R01 or equivalent grants.

CEP Awards will support new investigative cutaneous oncologists and other scientists committed to multidisciplinary studies investigating the relevance of biological discoveries in human skin cancer risk, prevention, diagnosis, prognosis or treatment, and enhance the careers of individuals who are already productively investigating this field.

**Application Deadline:** August 14, 2023

Read More

**2023 Yale SPORE in Skin Cancer Developmental Research Program Awards**
DRP projects must have promising translational research potential with application to human skin cancer. It is expected that they can evolve into full projects with a clear translational component that are suitable for funding either within the Yale SPORE in Skin Cancer or as independent R01 or R01-equivalent grants.

DRP Awards are intended to support a broad spectrum of innovative pilot projects applicable to human skin cancer risk, prevention, diagnosis, prognosis, or treatment.

**Application Deadline:** August 14, 2023

Read More

**DoD Melanoma Research Program Funding Opportunities**
The FY23 Defense Appropriations Act provides funding for the Melanoma Research Program (MRP) to support innovative, high-impact melanoma research.

- **Idea Award:** to generate novel research avenues for investigation; therefore, novelty and innovation should be key aspects of the project. The **Letter of Intent** must be submitted by August 11, 2023.

Read More

Jane Silvestro:
Finding out last fall that I had cancer was a bit of a shock, because I had no history in my family… But then again, I asked myself why NOT me, as cancer seems to be so prevalent and so often random. Anyway, what can a girl do but take care of business, follow doctors’ suggestions, etc. so I did.

I had heard that chemo treatments involve camaraderie and encouragement, at Smilow, and elsewhere, which I DID experience in a somewhat limited manner, because I kept falling sound asleep during my treatments. No one ever complained that I snored, but who knows? Even if everyone was talking about me, I would have been oblivious. During a Valentine’s Day treatment, though, I woke up long enough to be offered a delicious piece of pink-frosted cake, that another patient had apparently brought in to share. It was so sweet (in both senses of the word) and I wondered to myself, ‘what do I have to offer these lovely co-patients who I hardly get to chat with?’ I immediately thought of an answer...
To recognize and reward institutions whose biomedical, social, and accessibility in biomedical and behavioral research prize competition goals are as follows:

The prize competition goals are as follows:

**Accessibility in Biomedical and Behavioral Research Prize Competition**

NIH Institutional Excellence in Diversity, Equity, Inclusion, and Accessibility in Biomedical and Behavioral Research Prize Competition

The prize competition goals are as follows:
1. To recognize and reward institutions whose biomedical, social, and behavioral science schools, departments, centers, or divisions have identified gaps with respect to diversity, equity, inclusion, and accessibility (DEIA) and have designed, implemented, and evaluated interventions to address these gaps to achieve sustained improvement in DEIA within their faculty, postdoctoral scholars, and student bodies.

2. To identify effective practices for enhancing DEIA within faculty, postdoctoral scholars, and student bodies that are feasible and can be disseminated for adoption by other institutions.

**Application Deadline:** September 26, 2023

---

---

---

---

---
7th Annual Live Medical Crossfire: Hematologic Malignancies
July 22, 8:30 AM
Learn More

Yale Cancer Answers
July 23, 7:30 PM
WNPR 90.5
Using Digital Neurotherapy to Address Depression and Anxiety in Patients with Cancer
Bruce Wexler, MD
Learn More

Multidisciplinary Portal Hypertension and Vascular Liver Disorders Conference
July 25, 7:30 AM
Learn More

24th Annual International Lung Cancer Congress
July 27-29
Learn More

Smilow East Opening Celebration
July 28, 1:00 PM
55 Park Street Seminar Room
Learn More

Yale Cancer Answers
July 30, 7:30 PM
WNPR 90.5
New Research into the Early Detection of Ovarian Cancer
Stacy Malaker, PhD
Learn More

Share your news!
Please submit your recent publications, awards, and grant announcements to:

Renee Gaudette
Director, Public Affairs and Communications